Nieuws

Bij het bekijken van onderstaande persberichten verlaat u de Nederlandse Astellas website. U komt terecht op een andere website die niet onder de verantwoordelijkheid van Astellas Nederland valt.

Astellas and Theravance Announce Termination of License, Development and Commercialization Agreement for VIBATIV® (telavancin) for Injection (pdf 79KB)

Temporary Halt of Gaster-D 20mg Tablet Exports to Korea

AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-FreeSurvival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial (pdf 66KB)

Approval for Supplemental New Drug Application for the Selective COX-2 Inhibitor Celecox® Tablet in Japan (pdf 31KB)

Zogenix and Astellas Agree to End Co-Promotion for SUMAVEL® DosePro® Effective March 31, 2012

AstraZeneca Enters into Option Agreement to Acquire New Class of Diabetes Assets from Prosidion (pdf 45KB)

Favorable Immunogenicity and Tolerability Observed in Phase I/II Clinical Trialfor Seasonal Flu Vaccine ASP7374 (pdf 255KB)

European Commission Grants Marketing Authorisation for Astellas Pharma Europe Ltd.'s DIFICLIR? for use in the EU (pdf 152KB)

Astellas Receives Ireland Japan Chamber of Commerce Business Award -Ireland Plant's Wind Turbine and Wood Chip Boiler Recognized for Environmental Contribution -

Presentation Material of Press Conference on 21st November, 2011 (pdf 1.6KB)

Astellas Signs United Nations Global Compact